Kathrin Jansen
#50,754
Most Influential Person Now
Microbiologist and researcher
Kathrin Jansen's AcademicInfluence.com Rankings
Kathrin Jansenbiology Degrees
Biology
#2941
World Rank
#4580
Historical Rank
Virology
#243
World Rank
#250
Historical Rank
Microbiology
#253
World Rank
#294
Historical Rank
Download Badge
Biology
Kathrin Jansen's Degrees
- Bachelors Microbiology University of California, Berkeley
- Masters Microbiology Stanford University
Why Is Kathrin Jansen Influential?
(Suggest an Edit or Addition)According to Wikipedia, Kathrin U. Jansen is the former Head of Vaccine Research and Development at Pfizer. She previously led the development of the HPV vaccine and newer versions of the pneumococcal conjugate vaccine , and is working with BioNTech to create a COVID-19 vaccine using mRNA that was approved for Emergency Use Authorization in the United States on December 11, 2020.
Kathrin Jansen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020) (7900)
- A controlled trial of a human papillomavirus type 16 vaccine. (2002) (1763)
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (2020) (1707)
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. (2005) (1693)
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020) (1143)
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) (1069)
- Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. (2015) (918)
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months (2021) (727)
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (2021) (527)
- Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial (2006) (504)
- Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. (2006) (486)
- The L1 Major Capsid Protein of Human Papillomavirus Type 11 Recombinant Virus-like Particles Interacts with Heparin and Cell-surface Glycosaminoglycans on Human Keratinocytes* (1999) (426)
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) (413)
- Turning the corner on therapeutic cancer vaccines (2019) (382)
- BNT162b vaccines protect rhesus macaques from SARS-CoV-2 (2021) (339)
- Neutralizing Activity of BNT162b2-Elicited Serum (2021) (322)
- Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay (2003) (300)
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2021) (290)
- BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants (2021) (281)
- Associations between Health Effects and Particulate Matter and Black Carbon in Subjects with Respiratory Disease (2005) (272)
- A Novel Staphylococcus aureus Vaccine: Iron Surface Determinant B Induces Rapid Antibody Responses in Rhesus Macaques and Specific Increased Survival in a Murine S. aureus Sepsis Model (2006) (255)
- Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18 (2005) (249)
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 (2021) (240)
- Pulmonary Effects of Indoor- and Outdoor-Generated Particles in Children with Asthma (2005) (218)
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. (2013) (207)
- Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. (2010) (204)
- Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. (2009) (201)
- The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. (2011) (188)
- Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. (1995) (181)
- Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers (2010) (179)
- Protection against papillomavirus with a polynucleotide vaccine. (1996) (179)
- The role of vaccines in preventing bacterial antimicrobial resistance (2018) (167)
- BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans (2020) (154)
- Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report. (2021) (149)
- Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. (2010) (149)
- Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. (2012) (143)
- Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. (2013) (141)
- RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study (2020) (140)
- Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. (1997) (135)
- Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. (1995) (135)
- Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. (2014) (134)
- Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. (2012) (133)
- Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). (2006) (132)
- Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (2020) (126)
- Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. (2001) (122)
- Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine (2021) (122)
- A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates (2020) (113)
- Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. (2004) (113)
- Blood Pressure Response to Controlled Diesel Exhaust Exposure in Human Subjects (2012) (111)
- Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. (2011) (108)
- Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects". (2013) (106)
- Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease (2013) (105)
- Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus (2012) (105)
- Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureus. (2003) (103)
- Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine (2002) (101)
- Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. (1999) (100)
- Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention (2016) (100)
- A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. (2004) (98)
- Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. (2004) (96)
- Measurement of offline exhaled nitric oxide in a study of community exposure to air pollution. (2003) (96)
- Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine (2022) (95)
- Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine (2012) (94)
- Exhaled Nitric Oxide in Children with Asthma and Short-Term PM2.5 Exposure in Seattle (2005) (94)
- Establishment of a New Human Pneumococcal Standard Reference Serum, 007sp (2011) (93)
- Reproductive tract infections in rural women from the highlands, jungle, and coastal regions of Peru. (2004) (90)
- Staphylococcus aureus Manganese Transport Protein C Is a Highly Conserved Cell Surface Protein That Elicits Protective Immunity Against S. aureus and Staphylococcus epidermidis (2012) (90)
- Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors (2012) (88)
- Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine (2020) (86)
- Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. (2001) (86)
- Human papillomavirus vaccines and prevention of cervical cancer. (2004) (85)
- Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. (2019) (80)
- BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants (2021) (78)
- Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age (2020) (77)
- Correlation between Mouse Potency and In Vitro Relative Potency for Human Papillomavirus Type 16 Virus-Like Particles and Gardasil® Vaccine Samples (2005) (76)
- Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. (2009) (75)
- The Discovery and Development of a Novel Vaccine to Protect against Neisseria meningitidis Serogroup B Disease (2015) (75)
- The role of vaccines in fighting antimicrobial resistance (AMR) (2018) (73)
- A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile (2013) (72)
- Real-Time Monitoring of Bacterial Infection In Vivo: Development of Bioluminescent Staphylococcal Foreign-Body and Deep-Thigh-Wound Mouse Infection Models (2003) (72)
- A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. (2013) (69)
- Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. (2005) (68)
- Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia (2013) (68)
- Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae. (1996) (64)
- Fine Particulate Air Pollution and Cardiorespiratory Effects in the Elderly (2005) (63)
- Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. (2001) (62)
- Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. (2015) (62)
- A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. (2001) (61)
- Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. (2000) (60)
- Multilaboratory Comparison of Streptococcus pneumoniae Opsonophagocytic Killing Assays and Their Level of Agreement for the Determination of Functional Antibody Activity in Human Reference Sera (2010) (59)
- Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18–36 Months: A Phase 1 Randomized-controlled Clinical Trial (2012) (59)
- A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. (2015) (59)
- A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. (2016) (58)
- A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents (2013) (57)
- A Recombinant Clumping Factor A-Containing Vaccine Induces Functional Antibodies to Staphylococcus aureus That Are Not Observed after Natural Exposure (2012) (57)
- Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant (2005) (54)
- Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents (2015) (54)
- Three-dimensional structure and biophysical characterization of Staphylococcus aureus cell surface antigen-manganese transporter MntC. (2013) (53)
- Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. (2017) (52)
- Evaluation of a multilocus sequence typing system for Staphylococcus epidermidis. (2003) (51)
- SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. (2017) (51)
- Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 (2022) (51)
- Challenges for the evaluation of Staphylococcus aureus protein based vaccines: Monitoring antigenic diversity (2011) (50)
- A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults (2017) (50)
- A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization (2019) (49)
- Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. (2003) (49)
- Meningococcal serogroup B vaccines: Estimating breadth of coverage (2016) (48)
- The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease (2016) (48)
- Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine (2018) (47)
- Infectious Virions Produced from a Human Papillomavirus Type 18/16 Genomic DNA Chimera (2002) (47)
- Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. (2002) (47)
- Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. (1996) (46)
- Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine (2014) (46)
- Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. (2016) (45)
- Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine (2022) (45)
- Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. (2009) (44)
- Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. (2009) (44)
- Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics (2008) (42)
- Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination (2015) (42)
- From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine (2018) (41)
- Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease (2011) (41)
- Evaluation of Approaches to Monitor Staphylococcus aureus Virulence Factor Expression during Human Disease (2015) (41)
- A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. (2001) (40)
- Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays. (2006) (40)
- Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents (2016) (38)
- A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups (2013) (37)
- Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus‐like particle IgG concentration (1997) (37)
- Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. (2017) (37)
- Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial (2020) (36)
- Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains (2017) (36)
- HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. (2000) (36)
- Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine (2016) (35)
- Detection of specific human papillomavirus types in paraffin‐embedded sections of cervical carcinomas (2006) (33)
- Regulation of Staphylococcus aureus MntC Expression and Its Role in Response to Oxidative Stress (2013) (33)
- A population-based study of cervical carcinoma and HPV infection in Latvia. (2004) (32)
- Vaccine development to prevent Staphylococcus aureus surgical‐site infections (2017) (31)
- Pretreatment with Antioxidants Augments the Acute Arterial Vasoconstriction Caused by Diesel Exhaust Inhalation. (2016) (31)
- Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. (2017) (31)
- Poor Sensitivity of Polymerase Chain Reaction Assays of Genital Skin Swabs and Urine to Detect HPV 6 and 11 DNA in Men (2003) (30)
- Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes. (2005) (29)
- Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection. (2015) (28)
- Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections (2015) (28)
- New frontiers in meningococcal vaccines (2011) (27)
- Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection (2022) (27)
- Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study. (2017) (27)
- Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. (2017) (27)
- Potential impact of the bivalent rLP2086 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease (2012) (27)
- A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. (2021) (26)
- A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. (2016) (25)
- Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2021) (25)
- A Vaccine Approach for the Prevention of Infections by Multidrug-resistant Enterococcus faecium* (2015) (24)
- Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant (2010) (24)
- Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional Streptococcus pneumoniae Serotype–specific Polysaccharides in Human Urine (2020) (23)
- A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. (2006) (23)
- A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years (2019) (23)
- Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States (2019) (22)
- 13-valent Pneumococcal Conjugate Vaccine in Older Children and Adolescents Either Previously Immunized With or Naïve to 7-valent Pneumococcal Conjugate Vaccine (2014) (22)
- Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults (2014) (22)
- Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years (2021) (22)
- Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents. (2019) (21)
- Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. (2010) (21)
- Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. (2022) (20)
- Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development (2009) (20)
- BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2 (2020) (19)
- Preservative of choice for Prev(e)nar 13™ in a multi-dose formulation. (2011) (19)
- Vaccination strategies for the prevention of meningococcal disease (2018) (19)
- Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2021) (19)
- A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination (2021) (19)
- Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice. (2013) (17)
- The toxicity of mixtures of specific organophosphate compounds is modulated by paraoxonase 1 status. (2010) (17)
- Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines (2015) (16)
- Adult vaccination (2015) (16)
- Nonreplicating vaccines can protect african green monkeys from the memphis 37 strain of respiratory syncytial virus. (2013) (16)
- Paraoxonase (PON1) and Organophosphate Toxicity (2008) (16)
- DNA replicative functions of highly-expressed, codon-optimized human papillomavirus proteins E1 and E2. (2003) (15)
- Vaccines against cervical cancer (2004) (15)
- Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study (2017) (14)
- Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. (2022) (14)
- Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides (2018) (14)
- Two Vaccines for Staphylococcus aureus Induce a B-Cell-Mediated Immune Response (2018) (14)
- Vaccine innovations for emerging infectious diseases—a symposium report (2020) (13)
- Group A Streptococcal Carriage and Seroepidemiology in Children up to 10 Years of Age in Australia (2015) (13)
- Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection (2016) (12)
- Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years (2023) (12)
- Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States (2021) (12)
- Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. (2016) (12)
- Structure elucidation of capsular polysaccharides from Streptococcus pneumoniae serotype 33C, 33D, and revised structure of serotype 33B. (2014) (12)
- Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial (2018) (11)
- Anti-infective vaccination in the 21st century-new horizons for personal and public health. (2015) (11)
- Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. (2016) (10)
- Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine (2020) (10)
- Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. (2017) (10)
- Effectiveness of portable HEPA air cleaners on reducing indoor PM2.5 and NH3 in an agricultural cohort of children with asthma: A randomized intervention trial (2020) (10)
- Reviving an R&D pipeline: a step change in the Phase II success rate. (2020) (10)
- The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery (2018) (9)
- Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine (2022) (9)
- Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults (2018) (9)
- Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag) (2019) (9)
- Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes. (2003) (9)
- Identification of the common antigenic determinant shared by Streptococcus pneumoniae serotypes 33A, 35A, and 20 capsular polysaccharides. (2013) (9)
- Predicting pneumococcal community-acquired pneumonia in the emergency department: evaluation of clinical parameters. (2014) (8)
- Acute exposure to traffic-related air pollution alters antioxidant status in healthy adults. (2020) (8)
- Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease (2021) (8)
- Allergic and Respiratory Symptoms in Employees of Indoor Cannabis Grow Facilities. (2020) (8)
- Importance of specimen type in detecting human papillomavirus DNA from the female genital tract (2009) (8)
- Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen specific memory B cell repertoires (2017) (8)
- Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited sera (2021) (8)
- Virus-Like Particles as Vaccines and Vaccine Delivery Systems (2009) (8)
- The impact of human vaccines on bacterial antimicrobial resistance. A review (2021) (8)
- Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides (2018) (8)
- Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine. (2016) (7)
- Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults (2016) (7)
- A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine (2021) (7)
- Comparison of Phenotypic and Genotypic Approaches to Capsule Typing Neisseria (2015) (6)
- The NIH-led research response to COVID-19 (2023) (6)
- Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution. (2016) (6)
- 3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older (2020) (6)
- Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay (2017) (6)
- 1081Immunogenicity of Human Papilloma Vaccine Coadministered with an Investigational Bivalent rLP2086 Vaccine Against Meningococcal Serogroup B in Healthy Adolescents (2014) (5)
- A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States (2021) (5)
- Vaccination against Nosocomial Infections in Elderly Adults. (2020) (5)
- Randomized trial of a portable HEPA air cleaner intervention to reduce asthma morbidity among Latino children in an agricultural community (2021) (5)
- Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). (2020) (5)
- The home air in agriculture pediatric intervention (HAPI) trial: Rationale and methods. (2020) (5)
- A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec (2018) (5)
- A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults (2022) (5)
- Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches (2022) (5)
- Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16 (2005) (5)
- 2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate (2019) (4)
- Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine (2020) (4)
- Virus-like particles and E1-E4 protein expressed from the human papillomavirus type 11 bicistronic E1-E4-L1 transcript. (1996) (4)
- 13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model (2011) (4)
- Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. (2021) (4)
- 1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States (2020) (4)
- Effectiveness of portable HEPA air cleaners on reducing indoor endotoxin, PM10, and coarse particulate matter in an agricultural cohort of children with asthma: A randomized intervention trial. (2021) (4)
- BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants (2021) (4)
- Preclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli Infections (2022) (4)
- Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A. (2022) (3)
- The Role of Vaccines in Combating Antimicrobial Resistance (2021) (3)
- BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants (2022) (3)
- Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years. (2021) (3)
- The effect of complex traffic-related mixtures on blood pressure (2019) (3)
- Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. (2023) (3)
- Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine (2021) (3)
- Glycoconjugate Vaccines: The Clinical Journey (2018) (2)
- Validation of an Immunodiagnostic Assay for the Detection of 13 S. pneumoniae Serotype (2012) (2)
- Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2021) (2)
- Diastolic blood pressure effect of traffic-related air pollution: a trial of vehicle filtration (2018) (2)
- Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine (2021) (2)
- Safety, Tolerability and Immunogenicity of a Single Dose 4-Antigen or 3-Antigen Staphylococcus aureus Vaccine in Healthy Older Adults (2015) (2)
- Vaccines against human papillomaviruses (2010) (2)
- A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults. (2019) (2)
- Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B (2017) (2)
- S. aureus Colonization in Healthy Australian Adults Receiving an Investigational S. aureus 3-antigen Vaccine. (2019) (2)
- 1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age (2020) (1)
- Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age (2023) (1)
- A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age (2021) (1)
- Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. (2023) (1)
- Abstract 17098: Blood Pressure Response to Controlled Diesel Exhaust Inhalation in Human Subjects is Modified by Functional Variation in TRPV1 (2011) (1)
- Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease (2022) (1)
- Letter to the editor: Importance of serum bactericidal activity for estimating the breadth of protection for new meningococcal vaccines (2016) (1)
- Abstract 20747: Systolic Blood Pressure Response is Eliminated by Alpha 1 Adrenergic Blockade in Human Subjects (2016) (1)
- Toward vaccines against cervical cancer. (2004) (1)
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020) (1)
- Safety of MenB-FHbp (Bivalent rLP2086), a Meningococcal Serogroup B Vaccine, in Young Adults: Results from a Phase 3 Trial (2016) (1)
- Effectiveness of portable air cleaners to reduce indoor PM2.5 and NH3 in an agricultural cohort of children with asthma (2019) (1)
- New Pneumococcal Diagnostics---further ahead or more confused? (2014) (1)
- HPV-16 vaccine prevented persistent HPV-16 infection and the development of HPV-16 related cervical neoplasia (2003) (1)
- Horizontal transmission of cytomegalovirus in a rhesus model despite high-level, vaccine-elicited neutralizing antibody and T cell responses. (2022) (1)
- Changes in hematologic indices and inflammatory markers in a double-blind real world traffic exposure study (2018) (1)
- Vaccine Technology III: an ECI Conference held in Puerto Vallarta, Mexico from June 6-11, 2010. (2011) (1)
- BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants (2022) (1)
- A quadrivalent vaccine prevented persistent infection and disease associated with HPV types 6, 11, 16, and 18 (2005) (1)
- The path to developing a cervical cancer vaccine (2010) (0)
- Imunogeni sestavki antigenov Staphylococcusa aureusa (2010) (0)
- papillomavirus synthetic genes optimized for expression in human cells. (2000) (0)
- Special Issue: Advances in vaccine technology II 2008. (2009) (0)
- Optimized eksperession of HPV58 L1 in yeast (2004) (0)
- DEVELOPMENT OF A MULTI-DOSE FORMULATION FOR PREVNAR 13™ (2010) (0)
- 007spStandard Reference Serum, Establishment of a New Human (2014) (0)
- Diagnosticaccuracyofaserotypespecificantigentestin community-acquiredpneumonia (2013) (0)
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) (0)
- Expression optimized HPV 45 L1 in yeast. (2004) (0)
- VACCINE TECHNOLOGY II: Conference Program (2008) (0)
- 244. Development, Qualification, and Clinical Validation of an Immunodiagnostic assay for the Detection of 11 Additional S. pneumoniae Serotype-Specific Polysaccharides in Human Urine (2019) (0)
- 12. Randomized Studies of Two Clostridioides (Clostridium) difficile Vaccine Formulations (2020) (0)
- Effect of highway commuting on physiological stress (2019) (0)
- 91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization (2022) (0)
- Genetic variability factors in human susceptibility to organophosphorus compounds (2010) (0)
- Effect of In-Vehicle Exposure to Traffic-Related Air Pollution on Acute Arterial Vasoconstriction (0)
- Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older (2022) (0)
- Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STRIVE Randomized Clinical Trial. (2023) (0)
- Bacterial vaccines in development 1 (2015) (0)
- Stability of vaccine induced Th2 cells following intranasal infection with group A streptococcus (P4258) (2013) (0)
- Immunogenicity and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Tdap and MCV4 in US Adolescents (2015) (0)
- Inhalation Of Diesel Exhaust In Human Subjects And Expression Of Heme Oxygenase-1 In Peripheral Blood Leukocytes (2011) (0)
- Author response for "Effectiveness of portable HEPA air cleaners on reducing indoor PM 2.5 and NH 3 in an agricultural cohort of children with asthma: A randomized intervention trial" (2020) (0)
- Effects of Antioxidant Treatment in a Randomized Control Study of Diesel Exhaust Inhalation (2014) (0)
- Polipéptidos de fusión inmunogénicos (2014) (0)
- 2781. Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers (2019) (0)
- Associations between repeated measures of urinary phthalate metabolites and biomarkers of oxidative stress in a rural agricultural cohort of children with asthma. (2022) (0)
- Effect of Traffic-Related Air Pollution on Spontaneous Baroreceptor Sensitivity: A Trial of In-Vehicle Filtration (2018) (0)
- Papillomavirus manufacturing method (1996) (0)
- Clin. Vaccine Immunol.-2011-Goldblatt-1728-36[1] (2014) (0)
- 2134. A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Booster Dose of a Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6) (2022) (0)
- Indoor and Outdoor Residential Ammonia Concentrations in a Low-Income Cohort of Children with Asthma in an Area of Intensive Agricultural Production (2018) (0)
- Longitudinal measures of phthalate exposure and asthma exacerbation in a rural agricultural cohort of Latino children in Yakima Valley, Washington. (2022) (0)
- A process for the preparation of purified papilomavirusproteiner (1995) (0)
- Vaccin contre l'anthrax (2004) (0)
- The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease (2016) (0)
- Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2021) (0)
- Final Conference Program (2010) (0)
- Type 6A, the coding sequence for human papillomavirus DNA (1997) (0)
- The Dynamics of Staphylococcus aureus carriage and Comparisons by Age in Two Studies of an Investigational S aureus 4-Antigen Vaccine (SA4Ag) (2016) (0)
- Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine (2023) (0)
- Variants unlipidated antigen ORF2086 Neisseria meningitidis (2011) (0)
- Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old (2023) (0)
- Immunogenicity of MenB-FHbp (Bivalent rLP2086), a Meningococcal Serogroup B Vaccine, in US Adolescents: Results From a Phase 3 Trial (2016) (0)
- Synthetic virus particles with heterologous epitores. (1999) (0)
- 1337. Development, Maintenance, and Application of Opsonophagocytic Assays to Measure Functional Antibody Responses to Support a 20 Valent Pneumococcal Conjugate Vaccine (2019) (0)
- 16. A Randomized Phase 1 Study of a Novel Pneumococcal Conjugate Vaccine in Healthy Japanese Adults in the United States (2020) (0)
- Particules viroides synthetiques a epitopes heterologues (1999) (0)
- Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds (2023) (0)
- A process for producing purified papillomavirus proteins (1995) (0)
- Surgical Infection. (2017) (0)
- Protein delivery system using virus particles of human papillomavirus type. (1999) (0)
- 599Rapid rises in antibody titers observed following single dose administration of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) to healthy adults (2014) (0)
This paper list is powered by the following services:
Other Resources About Kathrin Jansen
What Schools Are Affiliated With Kathrin Jansen?
Kathrin Jansen is affiliated with the following schools:
